Breaking News Instant updates and real-time market news.

CARA

Cara Therapeutics

$9.22

-0.61 (-6.21%)

08:03
11/29/16
11/29
08:03
11/29/16
08:03

Cara Therapeutics completes planned enrollment of I.V. CR845 Phase 2/3 trial

Cara Therapeutics announced that it has completed patient enrollment for the multi-dose phase of its adaptive Phase 2/3 trial of I.V. CR845 in dialysis patients suffering from moderate-to-severe uremic pruritus, or UP. UP is an intractable systemic itch condition in patients with chronic kidney disease, or CKD, for which there are no approved therapies in the United States.

  • 29

    Nov

  • 01

    Dec

  • 02

    Dec

CARA Cara Therapeutics
$9.22

-0.61 (-6.21%)

12/31/15
PIPR
12/31/15
NO CHANGE
Target $34
PIPR
Overweight
Cara Therapeutics called a top 2016 pick at Piper Jaffray
Piper Jaffray analyst Charles Duncan highlights Cara Therapeutics (CARA) as his top pick going into 2016. The analyst likens the company's position to Neurocrine's (NBIX) last year, which he points out gained 150% at the end of 2014 to present. Cara has "notable value creation" potential from two Phase III read-outs of candidates with a "well-vetted mechanism of action in large-market indications," Duncan tells investors in a New Year's Eve research note. The analyst expects Cara's peak sales to reach four times its current market capitalization. He recommends buying the stock ahead of the Phase III readouts and keeps an Overweight rating on the stock with a $34 price target. Duncan expects the company to begin a pivotal trial of IV'845 in uremic pruritus in early 2016, with data being announced likely in Q4. Cara closed yesterday down 33c to $15.79 with a market cap of just below $440M.
02/26/16
CANT
02/26/16
NO CHANGE
CANT
Delay caused by Cara Therapeutics hold will be short, says Cantor
After Cara announced a clinical hold on the Phase III trial of its IV CR845 drug for post-surgical pain, the firm thinks the hold was unnecessary and does not expect it to delay the drug's advancement for more than three months. Cantor keeps a $28 price target and Buy rating on the shares.
10/13/16
HCWC
10/13/16
INITIATION
Target $20
HCWC
Buy
Cara Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Cara Therapeutics with a Buy rating and $20 price target. The company's CR845 presents an opportunity treat peripheral pain without addiction potential, the analyst contends.

TODAY'S FREE FLY STORIES

KMI

Kinder Morgan

$19.27

-0.5 (-2.53%)

13:50
09/21/17
09/21
13:50
09/21/17
13:50
Options
Kinder Morgan attracts call writers as shares slump »

Kinder Morgan attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRY

BlackBerry

$9.85

0.71 (7.77%)

13:45
09/21/17
09/21
13:45
09/21/17
13:45
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

13:45
09/21/17
09/21
13:45
09/21/17
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

ICPT

Intercept

$98.12

1.92 (2.00%)

13:41
09/21/17
09/21
13:41
09/21/17
13:41
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
09/21/17
09/21
13:40
09/21/17
13:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

HDSN

Hudson Technologies

$9.26

-0.03 (-0.32%)

13:39
09/21/17
09/21
13:39
09/21/17
13:39
Technical Analysis
Technical View: Hudson Technologies down on cautious Seeking Alpha mention »

The shares have taken a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

HDSN

Hudson Technologies

$9.26

-0.03 (-0.32%)

13:34
09/21/17
09/21
13:34
09/21/17
13:34
Periodicals
Hudson Technologies mentioned cautiously by Seeking Alpha contributor 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

OUT

Outfront Media

$21.19

-0.2 (-0.94%)

, LAMR

Lamar Advertising

$64.42

0.45 (0.70%)

13:30
09/21/17
09/21
13:30
09/21/17
13:30
Hot Stocks
Before the Move: Watch Outfront Media ahead of NYC-MTA contract decision »

A decision regarding the…

OUT

Outfront Media

$21.19

-0.2 (-0.94%)

LAMR

Lamar Advertising

$64.42

0.45 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ILG

ILG

$25.87

0.56 (2.21%)

, VAC

Marriott Vacations

$119.30

5.31 (4.66%)

13:24
09/21/17
09/21
13:24
09/21/17
13:24
Periodicals
FrontFour plans ILG proxy fight if deal not struck this year, Bloomberg says »

FrontFour Capital, a…

ILG

ILG

$25.87

0.56 (2.21%)

VAC

Marriott Vacations

$119.30

5.31 (4.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

DDAIF

Daimler AG

$79.46

-0.16 (-0.20%)

, TSLA

Tesla

$373.91

-1.19 (-0.32%)

13:21
09/21/17
09/21
13:21
09/21/17
13:21
Hot Stocks
Mercedes-Benz to start production of electric passenger cars in U.S. »

Mercedes-Benz will set up…

DDAIF

Daimler AG

$79.46

-0.16 (-0.20%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MSFT

Microsoft

$74.94

-0.5 (-0.66%)

13:20
09/21/17
09/21
13:20
09/21/17
13:20
Options
Notable call write in Microsoft »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

$NSD

NASDAQ Market Internals

13:17
09/21/17
09/21
13:17
09/21/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
09/21/17
09/21
13:16
09/21/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
09/21/17
09/21
13:15
09/21/17
13:15
General news
Treasury's $11 B 10-year TIPS reopening was poorly received »

Treasury's $11 B…

XOP

SPDR Oil Exploration and Production Fund

$32.88

0.02 (0.06%)

13:10
09/21/17
09/21
13:10
09/21/17
13:10
Options
Hefty put spread in SPDR Oil and Gas Exploration ETF »

Hefty put spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$43.92

0.32 (0.73%)

13:05
09/21/17
09/21
13:05
09/21/17
13:05
Options
TripAdvisor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:04
09/21/17
09/21
13:04
09/21/17
13:04
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

13:04
09/21/17
09/21
13:04
09/21/17
13:04
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

ZGNX

Zogenix

$13.60

-0.95 (-6.53%)

12:55
09/21/17
09/21
12:55
09/21/17
12:55
Options
Zogenix put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$21.55

0.6 (2.86%)

12:51
09/21/17
09/21
12:51
09/21/17
12:51
Periodicals
Impax merger with Amneal could come next month, WSJ reports »

Impax and Amneal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CAR

Avis Budget

$37.92

1.28 (3.49%)

12:40
09/21/17
09/21
12:40
09/21/17
12:40
Options
Avis attracts a put buyer »

Avis attracts a put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

12:40
09/21/17
09/21
12:40
09/21/17
12:40
General news
Treasury 10-year TIPS preview »

Treasury 10-year TIPS…

GIS

General Mills

$51.80

-0.3658 (-0.70%)

12:30
09/21/17
09/21
12:30
09/21/17
12:30
Options
Position adjustment in General Mills after earnings »

Position adjustment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$5.60

-0.08 (-1.41%)

12:29
09/21/17
09/21
12:29
09/21/17
12:29
Upgrade
Ericsson rating change  »

Ericsson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$6.09

-0.095 (-1.54%)

12:29
09/21/17
09/21
12:29
09/21/17
12:29
Downgrade
Nokia rating change  »

Nokia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.